Lubrizol’s Apisolex™ Polymer Wins Finished Formulation Award at CPhI Barcelona
Lubrizol Life Science Health, a leading pharmaceutical company, has won the Finished Formulation Award at CPhI Barcelona for its innovative technology – Apisolex™ Polymer solubilizing excipient. With over 180 entries covering 12 innovation categories featuring many of pharma’s biggest names, Apisolex Polymer was again recognized as a breakthrough innovation adding to the prestigious award recognized by The Medicine Maker earlier this year. The winners were announced at a networking reception held at CPhI Barcelona with over 500 guests in attendance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231024985629/en/
Kevin Song, Ph.D., Global Marketing Director accepts CPhI Award for Apisolex™ Polymer on behalf of The Lubrizol Corporation. (Photo: Business Wire)
Apisolex™ Polymer is the first solubility-enhancing excipient to be launched specifically for parenteral use in over 20 years. Comprised of building blocks naturally occurring in the body, Apisolex™ is a poly(amino acid)--based excipient that provides drug formulators with the necessary tools and methods to enhance the solubility of hydrophobic APIs by up to 50,000-fold.
Approximately 60% of new chemical entities (NCEs) under development, and more than 40% of Active Pharmaceutical Ingredients (APIs) in reformulation are poorly water-soluble with each requiring tailored solutions. With several solubilizing excipients on the market, it is impossible to find a one-size-fits-all solution. Filling a crucial gap in the market, Apisolex™ Polymer enables novel brick-dust and grease ball APIs to be formulated, as well as providing existing APIs with the option to be repurposed or reformulated via the FDA’s 505(b)(2) regulatory pathway.
“By drawing on our 40+ year legacy, Lubrizol Life Science Health has developed a non-immunogenic, biocompatible, and biodegradable alternative to PEG-based excipients. Apisolex™ Polymer offers oncology, CNS, and high-value orphan drug formulators the tools necessary to unlock the potential of previously hard-to-formulate APIs, providing patients with access to life-changing therapeutics that otherwise may not have made it to market.” - Gaurab Sengupta, Senior Global Business Director, Pharmaceuticals & Nutraceuticals, Lubrizol Life Science Health.
Request a sample or speak with a solubility enhancement expert today.
About Lubrizol
The Lubrizol Corporation, a Berkshire Hathaway company, is a specialty chemical company whose science delivers sustainable solutions to advance mobility, improve wellbeing and enhance modern life. Founded in 1928, Lubrizol owns and operates more than 100 manufacturing facilities, sales and technical offices around the world and has more than 8,000 employees. For more information, visit www.Lubrizol.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231024985629/en/
Contact information
Gabe Ellis
Global Marketing Communications Manager – Pharma
Gabe.ellis@lubrizol.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corona Global Named Most Valuable Beer Brand in Kantar BrandZ Rankings for Second Consecutive Year15.5.2025 07:01:00 EEST | Press release
Corona has been recognized as the most valuable beer brand in the world for the second consecutive year in Kantar's BrandZ 2025 Most Valuable Global Brands report, released today. Eight out of the 10 most valuable global beer brands belong to AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), according to the report ranking the top brands in the world. In 2024 AB InBev produced all-time high revenue and 15% Underlying EPS growth. The year marked double-digit growth for Corona outside of its home market of Mexico and triple-digit growth of its no-alcohol brand Corona Cero. Corona Cero is the first beer brand to sponsor the Olympic Games making its debut in Paris 2024. In 2025, Corona is celebrating its 100-year anniversary with events all over the world through its “Corona 100” platform. Corona is followed by Budweiser, the second most valuable beer brand in the world. Michelob ULTRA moved up one spot to #5 amongst beer brands globally. Michelob ULTRA has also been named the winner
Forrester Opens Nominations For Its 2025 B2B Awards In EMEA And APAC15.5.2025 07:00:00 EEST | Press release
Forrester (Nasdaq: FORR) today opened calls for nominations for its 2025 B2B Return On Integration Honors and B2B Programs Of The Year Awards in Asia Pacific (APAC) and Europe, Middle East, and Africa (EMEA). These awards will recognize B2B organizations based in both regions for achieving functional excellence and outstanding alignment across marketing, sales, and product — the B2B revenue engine — to improve customer experience and drive growth. Nominations for both award categories are open to organizations of all sizes in each region. B2B leaders across APAC and EMEA — including chief marketing officers, chief sales officers, chief product officers, and other marketing, sales, and product leaders — are invited and encouraged to apply. To be eligible, programs need to be developed by leaders and teams based in the APAC or EMEA regions. The nomination criteria for the two awards are as follows: B2B Return On Integration (ROI) Honors. These awards showcase organizations that have achi
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 05:00:00 EEST | Press release
Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese market by optimizing their website UI/UX, thereby enhancing the effectiveness of their Google Ads campaigns. Background of the Partnership Known as a "Start-up Nation," Israel is home to many
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 04:11:00 EEST | Press release
Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14th edition of Nat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom